Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 2—February 2020
Research

Neutralizing Antibodies against Enteroviruses in Patients with Hand, Foot and Mouth Disease

Lam Anh NguyetComments to Author , Tran Tan Thanh, Le Nguyen Thanh Nhan, Nguyen Thi Thu Hong, Le Nguyen Truc Nhu, Hoang Minh Tu Van, Nguyen Thi Han Ny, Nguyen To Anh, Do Duong Kim Han, Ha Manh Tuan, Vu Quang Huy, Ho Lu Viet, Hoang Quoc Cuong, Nguyen Thi Thanh Thao, Do Chau Viet, Truong Huu Khanh, Louise Thwaites, Hannah Clapham, Nguyen Thanh Hung, Nguyen Van Vinh Chau, Guy Thwaites, Do Quang Ha, H. Rogier van Doorn, and Le Van TanComments to Author 
Author affiliations: Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (L.A. Nguyet, T.T. Thanh, N.T.T. Hong, L.N.T. Nhu, H.M.T. Van, N.T.H. Ny, N.T. Anh, D.D.K. Han, L. Thwaites, H. Clapham, G. Thwaites, D.Q. Ha, H.R. van Doorn, L.V. Tan); Children’s Hospital 1, Ho Chi Minh City (L.N.T. Nhan, T.H. Khanh, N.T. Hung); Children’s Hospital 2, Ho Chi Minh City (H.M. Tuan, H.L. Viet, D.C. Viet); University of Medicine and Pharmacy, Ho Chi Minh City (H.M. Tuan, V.Q. Huy); Pasteur Institute, Ho Chi Minh City (H.Q. Cuong, N.T.T. Thao); University of Oxford, Oxford, UK (L. Thwaites, H. Clapham, G. Thwaites, H.R. van Doorn); Hospital for Tropical Diseases, Ho Chi Minh City (N.V.V. Chau)

Main Article

Table 2

Seropositivity and seroconversion in plasma from hand, foot and mouth disease patients infected with EV-A71, CVA6, CVA10, and CVA16 viruses, Vietnam*

Virus Immunity status Virus, no. (%) samples
CVA6 CVA10 CVA16 EV-A71
CVA6 Seropositivity
At enrollment 2 (7) 10 (33) 5 (17) 2 (7)
At follow-up 30 (100) 9 (30) 9 (30) 3 (10)
p value <0.001 1.0 0.36 1.0
Seroconversion
 28 (93)
 1 (3)
 7 (23)
 2 (7)
CVA10 Seropositivity
At enrollment 4 (13) 9 (30) 3 (10) 3 (10)
At follow-up 6 (20) 29 (97) 4 (13) 5 (17)
p value 0.73 <0.001 1.0 0.71
Seroconversion
 4 (13)
 25 (83)
 3 (10)
 2 (7)
CVA16 Seropositivity
At enrollment 7 (23) 10 (33) 8 (27) 5 (17)
At follow-up 9 (30) 11 (37) 30 (100) 7 (23)
p value 0.77 1.0 <0.001 0.75
Seroconversion
 3 (10)
 2 (7)
 23 (77)
 2 (7)
EV-A71 Seropositivity
At enrollment 5 (17) 17 (57) 6 (20) 18 (60)
At follow-up 7 (23) 14 (47) 8 (27) 30 (100)
p value 0.75 0.61 0.76 <0.001
Seroconversion 4 (13) 1 (3) 3 (10) 17 (57)

*n = 30 for each virus. p values reflect the results of statistical analysis comparing the seropositive rates between the 2 time points (enrollment and follow-up) of the corresponding enterovirus serotypes. CV, coxsackievirus; EV, enterovirus.

Main Article

Page created: January 17, 2020
Page updated: January 17, 2020
Page reviewed: January 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external